Switch theme
Sign up to access all valuation multiples
Shijiazhuang Yiling Pharmaceutical Co Ltd is a China-based company that engages in pharmaceutical manufacturing. The company is principally engaged in the research, development, manufacturing, and sales of traditional Chinese pharmaceutical products, especially in the fields of cardiovascular and cerebrovascular diseases, respiratory diseases, tumor, diabetes, and related complications. Its products include drug series, chemical drugs, Chinese medicine series, and health products.
2001
n/a
LTM Revenue $1.1B
LTM EBITDA -$35.9M
$3.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Shijiazhuang Yiling has a last 12-month revenue (LTM) of $1.1B and a last 12-month EBITDA of -$35.9M.
In the most recent fiscal year, Shijiazhuang Yiling achieved revenue of $904M and an EBITDA of -$22.2M.
Shijiazhuang Yiling expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Shijiazhuang Yiling valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.1B | XXX | $904M | XXX | XXX | XXX |
| Gross Profit | $570M | XXX | $454M | XXX | XXX | XXX |
| Gross Margin | 52% | XXX | 50% | XXX | XXX | XXX |
| EBITDA | -$35.9M | XXX | -$22.2M | XXX | XXX | XXX |
| EBITDA Margin | -3% | XXX | -2% | XXX | XXX | XXX |
| EBIT | $22.9M | XXX | -$62.1M | XXX | XXX | XXX |
| EBIT Margin | 2% | XXX | -7% | XXX | XXX | XXX |
| Net Profit | $8.9M | XXX | -$101M | XXX | XXX | XXX |
| Net Margin | 1% | XXX | -11% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Shijiazhuang Yiling's stock price is CNY 15 (or $2).
Shijiazhuang Yiling has current market cap of CNY 24.3B (or $3.4B), and EV of CNY 23.2B (or $3.2B).
See Shijiazhuang Yiling trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.2B | $3.4B | XXX | XXX | XXX | XXX | $0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Shijiazhuang Yiling has market cap of $3.4B and EV of $3.2B.
Shijiazhuang Yiling's trades at 3.6x EV/Revenue multiple, and -145.4x EV/EBITDA.
Equity research analysts estimate Shijiazhuang Yiling's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Shijiazhuang Yiling has a P/E ratio of 380.3x.
See valuation multiples for Shijiazhuang Yiling and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.4B | XXX | $3.4B | XXX | XXX | XXX |
| EV (current) | $3.2B | XXX | $3.2B | XXX | XXX | XXX |
| EV/Revenue | 2.9x | XXX | 3.6x | XXX | XXX | XXX |
| EV/EBITDA | -89.6x | XXX | -145.4x | XXX | XXX | XXX |
| EV/EBIT | 140.8x | XXX | -51.9x | XXX | XXX | XXX |
| EV/Gross Profit | 5.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 380.3x | XXX | -33.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 72.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialShijiazhuang Yiling's last 12 month revenue growth is 32%
Shijiazhuang Yiling's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Shijiazhuang Yiling's rule of 40 is 54% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Shijiazhuang Yiling's rule of X is 77% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Shijiazhuang Yiling and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 32% | XXX | 31% | XXX | XXX | XXX |
| EBITDA Margin | -3% | XXX | -2% | XXX | XXX | XXX |
| EBITDA Growth | -645% | XXX | -24% | XXX | XXX | XXX |
| Rule of 40 | 54% | XXX | 30% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 77% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 21% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 13% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 57% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Shijiazhuang Yiling acquired XXX companies to date.
Last acquisition by Shijiazhuang Yiling was XXXXXXXX, XXXXX XXXXX XXXXXX . Shijiazhuang Yiling acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Shijiazhuang Yiling founded? | Shijiazhuang Yiling was founded in 2001. |
| Where is Shijiazhuang Yiling headquartered? | Shijiazhuang Yiling is headquartered in China. |
| Is Shijiazhuang Yiling publicy listed? | Yes, Shijiazhuang Yiling is a public company listed on SHE. |
| What is the stock symbol of Shijiazhuang Yiling? | Shijiazhuang Yiling trades under 002603 ticker. |
| When did Shijiazhuang Yiling go public? | Shijiazhuang Yiling went public in 2011. |
| Who are competitors of Shijiazhuang Yiling? | Similar companies to Shijiazhuang Yiling include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Shijiazhuang Yiling? | Shijiazhuang Yiling's current market cap is $3.4B |
| What is the current revenue of Shijiazhuang Yiling? | Shijiazhuang Yiling's last 12 months revenue is $1.1B. |
| What is the current revenue growth of Shijiazhuang Yiling? | Shijiazhuang Yiling revenue growth (NTM/LTM) is 32%. |
| What is the current EV/Revenue multiple of Shijiazhuang Yiling? | Current revenue multiple of Shijiazhuang Yiling is 2.9x. |
| Is Shijiazhuang Yiling profitable? | Yes, Shijiazhuang Yiling is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Shijiazhuang Yiling? | Shijiazhuang Yiling's last 12 months EBITDA is -$35.9M. |
| What is Shijiazhuang Yiling's EBITDA margin? | Shijiazhuang Yiling's last 12 months EBITDA margin is -3%. |
| What is the current EV/EBITDA multiple of Shijiazhuang Yiling? | Current EBITDA multiple of Shijiazhuang Yiling is -89.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
